The FDA is expected to make a final decision in the coming months.
An advisory committee for the Food and Drug Administration voted Friday to recommend a peanut allergy treatment for FDA approval.
“From a science standpoint, this is a breakthrough,” said Dr. Bruce Lanser, a pediatric allergist and immunologist and director of the pediatric food allergy program at National Jewish Health in Denver. Lanser ran one arm of the clinical trials on the treatment. The panelists said the medication was an important option for parents and children dealing with peanut allergies. However, several also said they had concerns because the pill has to be taken continuously to maintain its effect.
After one year, about 66 percent of study participants who took the pills could tolerate the equivalent of three to four peanuts, compared to just 4 percent of patients who received a dummy treatment. At the beginning of the study, most participants could not tolerate even a minuscule amount of peanuts.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Mexico gives struggling Pemex $5 bln to pay debt, refinancing plannedRatings agencies gave a cautiously positive assessment on Wednesday of Mexico&0...
Consulte Mais informação »
AB InBev set to revive Budweiser Asia IPO with $5 billion float: sourcesThe world's largest brewer, Anheuser-Busch InBev , which shelved a Hong Kon...
Consulte Mais informação »
Mexico's $5 billion debt bailout for Pemex 'a one off': deputy ministerMexico's $5 billion rescue package to pay down debt at Pemex [PEMX.UL] is a...
Consulte Mais informação »
FDA takes major step toward approving first peanut allergy treatmentAn FDA committee voted in favor of approving a treatment for peanut allergies in children. If the full FDA votes for it, it would be the first FDA-approved treatment for peanut allergy.
Consulte Mais informação »
GE Healthcare earned FDA clearance for its AI-powered portable x-rayGE Healthcare earned the FDA's approval for its AI-powered mobile X-ray device – marking the first time the FDA has cleared a tool of its kind.
Consulte Mais informação »